UY37378A - Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus - Google Patents

Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus

Info

Publication number
UY37378A
UY37378A UY0001037378A UY37378A UY37378A UY 37378 A UY37378 A UY 37378A UY 0001037378 A UY0001037378 A UY 0001037378A UY 37378 A UY37378 A UY 37378A UY 37378 A UY37378 A UY 37378A
Authority
UY
Uruguay
Prior art keywords
piridazinone
fusioned
compounds useful
tricyclic compounds
treat
Prior art date
Application number
UY0001037378A
Other languages
English (en)
Inventor
Daniel Poon
R Taft Benjamin
Rama Jain
Christofer Koester Dennis
Vanessa Marx
Clifford Sutton James
Lifeng Wan
Qian Zhao
Aregahegn Yifru
R Manning James
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37378A publication Critical patent/UY37378A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La invención proporciona compuestos de la Fórmula (I), como se describe adicionalmente en la presente, así como composiciones farmacéuticas que comprenden dichos compuestos, y procedimientos para usar los compuestos y composiciones farmacéuticas para el tratamiento de ciertos trastornos víricos, incluyendo la influenza
UY0001037378A 2016-08-29 2017-08-28 Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus UY37378A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662380712P 2016-08-29 2016-08-29

Publications (1)

Publication Number Publication Date
UY37378A true UY37378A (es) 2018-03-23

Family

ID=59923494

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037378A UY37378A (es) 2016-08-29 2017-08-28 Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus

Country Status (15)

Country Link
US (3) US11098051B2 (es)
EP (3) EP4356969A2 (es)
JP (2) JP7221861B2 (es)
CN (2) CN109863151B (es)
AR (1) AR109438A1 (es)
CA (1) CA3035302A1 (es)
ES (1) ES2859510T3 (es)
JO (1) JOP20170169A1 (es)
MX (1) MX2019002438A (es)
PL (2) PL3848372T3 (es)
PT (2) PT3504214T (es)
SI (2) SI3848372T1 (es)
TW (2) TWI803467B (es)
UY (1) UY37378A (es)
WO (1) WO2018042303A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923075C (en) * 2013-09-12 2022-07-26 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
RU2745071C2 (ru) 2015-12-15 2021-03-18 Сионоги Энд Ко., Лтд. Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
CN110494141A (zh) 2016-08-10 2019-11-22 盐野义制药株式会社 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CA3088926A1 (en) 2018-01-17 2019-07-25 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
MX2020008959A (es) * 2018-02-28 2020-10-05 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza.
CN108440564B (zh) * 2018-04-11 2019-08-06 安帝康（无锡）生物科技有限公司 被取代的多环氨基甲酰基吡啶酮衍生物及其前药
JP2022512676A (ja) * 2018-10-10 2022-02-07 ヤンセン バイオファーマ インク． 大環状インフルエンザエンドヌクレアーゼ阻害剤
WO2022105669A1 (zh) * 2020-11-17 2022-05-27 南京明德新药研发有限公司 含Se大环类化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501542D0 (en) 1985-01-22 1985-02-20 Erba Farmitalia 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives
AUPM354694A0 (en) 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
JP4338192B2 (ja) 2001-08-10 2009-10-07 塩野義製薬株式会社 抗ウイルス剤
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
FR2901795A1 (fr) 2006-05-30 2007-12-07 Fourtillan Snc Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique
RS55365B1 (sr) 2008-10-31 2017-03-31 Shionogi & Co Cefalosporin sa kateholskom grupom
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
LT2444400T (lt) * 2009-06-15 2018-06-11 Shionogi & Co., Ltd. Pakeistasis policiklinis karbamoilpiridono darinys
JP2013515734A (ja) 2009-12-23 2013-05-09 エラン ファーマシューティカルズ，インコーポレイテッド ポロ様キナーゼの阻害薬としてのプテリジノン
US8541407B2 (en) 2010-03-31 2013-09-24 Arqule, Inc. Substituted benzo-pyrido-triazolo-diazepine compounds
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
HUE039859T2 (hu) * 2010-09-24 2019-02-28 Shionogi & Co Helyettesített policiklusos karbamoil-piridon-származék prodrug
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
AU2012321762A1 (en) * 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
KR101520302B1 (ko) 2012-09-20 2015-05-15 (주)셀트리온 돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
SG11201600977XA (en) 2013-08-21 2016-03-30 Alios Biopharma Inc Antiviral compounds
US10098913B2 (en) 2013-09-11 2018-10-16 University Of Southern California Composition of stem cells having highly expressed FAS ligand
CA2923075C (en) * 2013-09-12 2022-07-26 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
MX370085B (es) 2013-09-12 2019-11-29 Janssen Biopharma Inc Compuestos de piridazinona y usos de los mismos.
JP2017521424A (ja) 2014-07-07 2017-08-03 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ウイルス疾患の治療、改善又は予防におけるジヒドロピリドピラジン−１，８−ジオン及びそれらの使用
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
CN110494141A (zh) 2016-08-10 2019-11-22 盐野义制药株式会社 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP2019059697A (ja) * 2017-09-28 2019-04-18 塩野義製薬株式会社 置換された多環性ピリダジン誘導体およびそのプロドラッグ
CN110041327B (zh) 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CA3088926A1 (en) 2018-01-17 2019-07-25 Jiangxi Caishi Pharmaceutical Technology Co., Ltd. Pyridone derivative, composition and use as antiviral drug thereof
CA3087994A1 (en) 2018-02-28 2019-09-06 Japan Tobacco Inc. 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
JP7200005B2 (ja) 2018-02-28 2023-01-06 日本たばこ産業株式会社 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
MX2020008959A (es) 2018-02-28 2020-10-05 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza.
AU2019228654A1 (en) 2018-02-28 2020-09-03 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Also Published As

Publication number Publication date
EP3848372A1 (en) 2021-07-14
US20180057501A1 (en) 2018-03-01
JP7221861B2 (ja) 2023-02-14
PT3504214T (pt) 2021-03-04
AR109438A1 (es) 2018-11-28
US10160764B2 (en) 2018-12-25
JOP20170169A1 (ar) 2019-01-30
US11912715B2 (en) 2024-02-27
EP4356969A2 (en) 2024-04-24
PL3504214T3 (pl) 2021-07-19
TWI803467B (zh) 2023-06-01
TW202342482A (zh) 2023-11-01
CA3035302A1 (en) 2018-03-08
ES2859510T3 (es) 2021-10-04
CN109863151B (zh) 2021-09-10
US11098051B2 (en) 2021-08-24
SI3848372T1 (sl) 2024-04-30
WO2018042303A1 (en) 2018-03-08
CN109863151A (zh) 2019-06-07
CN113683614A (zh) 2021-11-23
US20200123167A1 (en) 2020-04-23
EP3848372B1 (en) 2023-12-20
SI3504214T1 (sl) 2021-04-30
US20220041610A1 (en) 2022-02-10
PL3848372T3 (pl) 2024-04-22
JP2023027102A (ja) 2023-03-01
EP3504214B1 (en) 2020-12-02
MX2019002438A (es) 2019-07-08
TW201811800A (zh) 2018-04-01
JP2019532033A (ja) 2019-11-07
PT3848372T (pt) 2024-03-22
EP3504214A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019002204A1 (es) Compuestos inhibidores del vih.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
UY37128A (es) Compuestos tetracíclicos de piridona como antivirales
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
EA201690372A1 (ru) Азапиридоновые соединения и их применение
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
PE20170440A1 (es) Derivados de isoindolina
UY36221A (es) Derivados de isoindolinona
CO2020005420A2 (es) Compuestos antibacterianos
DOP2016000211A (es) Pirazinas moduladoras de gpr6